Stocktoria
Cronos Group Inc. CRON
Nasdaq · XNAS · stock · Medicinal Chemicals & Botanical Products · website · IPO 2014-05-07
Cronos Group Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 32.5% | 15.6% | 9.9% | 14.1% | -22.1% |
| Operating margin | -9.0% | -47.3% | -70.5% | -101.9% | -366.7% |
| Net margin | -4.9% | 25.4% | -61.5% | -154.4% | -497.5% |
| FCF margin | 0.1% | 4.0% | -37.7% | -84.5% | -207.0% |
| Return on assets | -0.8% | 3.5% | -6.5% | -13.9% | -28.3% |
| Return on equity | -0.8% | 3.7% | -6.7% | -14.8% | -29.6% |
| Current ratio | 19.59 | 18.84 | 22.54 | 14.10 | 19.86 |
| Revenue growth | 19.5% | 34.5% | 10.0% | 37.3% | 46.5% |
Source: SEC EDGAR filings · CIK 0001656472 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.